ArticleFrontiers in cell and developmental biology2026
Therapeutic potential of maggot-derived bioactive peptides in modulating inflammatory responses in mice model of inflammatory bowel disease.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammatory bowel disease (IBD) is characterized by chronic inflammation and disruption of intestinal integrity. This study investigates the therapeutic effects of Maggot-Derived Bioactive Peptides (BPM) in alleviating IBD symptoms and restoring intestinal function. Methods: Using an IBD model, we assessed the impact of BPM on inflammatory responses, intestinal morphology, goblet cell density, and tight junction protein expression. Serum levels of inflammatory and oxidative stress markers were also measured to evaluate systemic effects. Results: BPM significantly alleviated inflammatory responses in IBD, as evidenced by decreased levels of pro-inflammatory cytokines, including TNF-α. Treatment with BPM enhanced intestinal morphology and increased goblet cell density, promoting mucosal barrier function. Furthermore, BPM regulated p-p65 and TNF-α pathways, effectively mitigating inflammation. Serum analysis revealed that BPM modulated the expression of inflammatory and oxidative stress markers. Importantly, BPM preserved intestinal wall integrity by upregulating tight junction proteins ZO-1, occludin, and claudin-1. Discussion: Our findings suggest that BPM is a promising therapeutic agent for IBD, exerting anti-inflammatory effects, enhancing intestinal morphology, and preserving epithelial integrity through multiple mechanisms. Further investigations are warranted to explore BPM's potential as a standard treatment option for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.